Biotechnology company InduPro Inc announced on Wednesday that it has entered into a strategic equity investment and research collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY).
The agreement includes a right of first negotiation for Sanofi on InduPro's bispecific PD-1 agonist programme, currently in preclinical development for the treatment of autoimmune and inflammatory disorders.
Sanofi will fund preclinical and IND-enabling research activities and make an undisclosed equity investment in InduPro.
InduPro leverages high-resolution proximity labelling technology to map membrane protein neighbourhoods, identifying novel co-target pairs for precise therapeutic intervention. The company's approach aims to create first-in-class and best-in-class therapeutic candidates by modulating cellular signalling pathways across multiple disease contexts.
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Champions Oncology expands bioanalytical services with new technology and leadership
Poolbeg Pharma trial to feature in major CRS research programme
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Natera acquires Foresight Diagnostics to expand MRD capabilities
OncoHost named Gold Winner in 2025 Merit Awards for Healthcare
Innovent Biologics and Takeda sign global strategic partnership
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)